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ABSTRACT
Zika virus has been associated with a wide range 
of neurological complications. Neurologists in 
areas without current active transmission of the 
virus may be confronted with Zika-associated 
neurological disease, as a large number of 
returning travellers with Zika virus infection have 
been reported and the virus continues to spread 
to previously unaffected regions. This review 
provides an overview of Zika virus-associated 
neurological disease and aims to support 
neurologists who may encounter patients 
returning from endemic areas.
InTRoduCTIon
The exponential increase in travelling 
has major consequences for the epide-
miology of infectious and postinfectious 
disease, constituting a global public 
health challenge.1 The most recent 
example of this is the Zika virus (ZIKV) 
epidemic in Latin America that has now 
spread to 84 countries globally and has 
been associated with severe neurological 
sequelae, including microcephaly, Guil-
lain-Barré syndrome (GBS) and central 
nervous system (CNS) disorders.2 
Regions without active transmission, 
including Europe, East Asia and North 
America, should still be on high alert, 
as large numbers of returning travellers 
with ZIKV infection have been reported 
and parts of these regions are predicted 
to be at risk for active viral transmis-
sion during the summer months.3–5 This 
review aims to support neurologists 
who may see travellers with neurolog-
ical complications returning from ZIKV 
endemic areas.
Transmission
ZIKV is an enveloped positive-strand 
RNA member of the Flavivirus genus 
in the Flaviviridae family. Other flavi-
viruses include dengue, yellow fever, 
West Nile virus and Japanese encepha-
litis virus, many of which are associated 
with neurological disease.6 Like these 
viruses, ZIKV is principally transmitted 
by a mosquito bite and is thus described 
as an arthropodborne virus or ‘arbo-
virus’. Its most prolific vector is the 
Aedes aegypti mosquito, which trans-
mits the virus between humans and is 
widespread in tropical regions globally 
(figure 1). Other Aedes mosquitos that 
populate more temperate regions, such 
as Aedes albopictus, can also facilitate 
viral spread but do so less effectively.7
Direct transmission between humans 
can occur vertically from mother to fetus, 
via blood transfusion, and by sexual 
contact; the latter accounts for an esti-
mated 1% of ZIKV cases in Europe.8 9 
Thus, while human-to-human transmis-
sion is far less common than conven-
tional arboviral transmission, it remains 
important to elicit a history of potential 
exposure to contacts that might have led 
to subsequent infection.
Geographical spread
ZIKV derives its name from the Zika forest 
in Uganda where it was identified in 1947. 
The first outbreak was reported in Micro-
nesia in 2007, 60 years after its discovery. 
The link between ZIKV and neurological 
complications was first recognised when 
an epidemic in French Polynesia in 2013 
was followed by a 20-fold increase in 
incidence of GBS cases.10 It is unclear if 
a change in viral strain altered its patho-
genicity, or whether the high incidence 
of infection resulted in a noticeably large 
number of otherwise rare neurological 
manifestations. Recent data suggest a 
mutation in the virus’s non-structural 1 
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Figure 1 Aedes mosquito.
Figure 2 Map of high- and low-risk areas for infection.
Box 1 Useful links
 ► Public Health England https://www.
gov.uk/government/collections/
zika-virus-zikv-clinical-and-travel-guidance.
 ► WHO http://www.who.int/emergencies/zika-virus/en/.
 ► Centers for Disease Control and Prevention https://
www.cdc.gov/zika/.
 ► European Centre for Disease Prevention and Control 
https://ecdc.europa.eu/en/zika-virus-infection.
 ► The National Travel Health Network and Centre https://
travelhealthpro.org.uk/countries.
protein, occurring around 2013, might promote the 
acquisition of the virus by its mosquito vector, thus 
enhancing its transmission in recent epidemics.11
Cases were next reported in Brazil in early 2015, 
where the virus went on to affect an estimated 
0.5–1.5 million people. During these months, there 
were alarming increases of reported microcephaly 
and GBS cases, prompting the WHO to declare ZIKV 
a Public Health Emergency of International Concern 
on 1 February 2016. The virus has since spread to a 
further 84 countries in the Americas, Africa and Asia, 
including 225 cases through presumed local mosqui-
toborne transmission in Southern states of the USA.2
Despite the decreasing trend of ZIKV infection in 
the Americas in 2017, the global health community 
advocates vigilance as it is unclear where and when 
the next outbreak will take place. Models predict that 
South and Southeast Asia and Oceania are at high 
risk for future outbreaks, with seasonal transmission 
a possible threat in southern parts of North America, 
China and Europe3 4 (figure 2).
While there has been no local spread reported in 
Europe and transmission has ceased in North America, 
there have been approximately 2130 travel-imported 
cases in Europe and around 5500 travel-imported cases 
in the USA since the start of the Brazilian epidemic.12 13 
In clinical practice, suspicion of ZIKV or related arbo-
viral infections, including dengue and chikungunya 
virus, should be high in anyone returning from—or 
in close contact with people returning from—endemic 
areas. We recommend checking the websites of Public 
Health England, WHO, National Travel Health 
Network and Centre, Centers for Disease Control and 
Prevention, or European Centre for Disease Preven-
tion and Control for the latest updates regarding ZIKV 
spread and travel advice (box 1).
Systemic symptoms
ZIKV has an estimated incubation period of 3–10 days 
and can remain asymptomatic in approximately 80% 
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Table 1 Clinical features of arboviruses
Zika virus
Dengue 
virus
Chikungunya 
virus
Fever ++ +++ +++
Rash (maculopapular) +++ + ++
Conjunctivitis ++ − − 
Arthralgia ++ + +++
Myalgia + ++ +
Headache + ++ ++
Shock − + +/−
Haemorrhage − + − 
Reproduced from the Centers for Disease Control and Prevention.39
Box 2 Neurological conditions associated with Zika
 ► Congenital Zika syndrome.
 ► Peripheral nervous system*:
 – Guillain-Barré syndrome.
 – Chronic inflammatory demyelinating 
polyneuropathy.
 – Acute transient polyneuritis.
 ► Central nervous system*:
 – (Meningo)encephalitis.
 – Myelitis.
 – Acute disseminated encephalomyelitis (ADEM).
 – Encephalopathy.
*There have also been some cases of combined central and 
peripheral disease.17
Box 3 Guillain-Barré syndrome in a returning 
traveller40
 A 60-year-old woman who had returned to the Neth-
erlands from Suriname 10 days before presented with 
diarrhoea, low-grade fever, nausea and vomiting, and an 
unsteady gait. Over 4 days, she developed bilateral facial 
palsy, symmetrical paresis of all limbs and distal hypoes-
thesia with low to absent tendon reflexes. Cerebrospinal 
fluid (CSF) had a normal cell count and increased protein 
concentration; electrophysiology showed signs of a demy-
elinating polyneuropathy. Her urine and blood were posi-
tive for Zika virus (ZIKV) RNA, and serology for other 
recent infections associated with Guillain-Barré syndrome 
(GBS) was negative. She received a 5-day course of intra-
venous immunoglobulin (0.4 g/L daily). At 1-year follow-up 
she was limited in her daily activities by fatigue and minor 
weakness in the legs but could walk without aid and had 
returned to part-time work.
of cases.14 Therefore, the absence of a febrile illness 
history does not exclude the diagnosis. Symptomatic 
infection is characterised by fever, rash, non-purulent 
conjunctivitis and arthralgia lasting up to a week, but 
may often also present as only a rash without fever 
or other accompanying signs and symptoms.14 These 
symptoms resemble those of other vectorborne viruses 
such as dengue and chikungunya virus, although a mild 
disease course with conjunctivitis is more specific for 
ZIKV (table 1). As such, it is the neurological features, 
rather than the systemic ones, that are the main cause 
of disability and death.
neuRoloGICAl ComplICATIonS oF ZIKV In The 
AdulT
ZIKV is known to be neurotropic: in neural progen-
itor cells infection it halts proliferation and may 
induce cell death, which is the likely disease mecha-
nism of ZIKV-related microcephaly cases.15 16 Beyond 
congenital Zika, direct viral invasion as well as a para-
infective or postinfective autoimmune response may 
contribute to pathogenesis. Box 2 lists the wide range 
of neurological problems associated with acute ZIKV 
infection.17
As such, any traveller returning from an area with 
ZIKV transmission, or with a sexual partner who has 
returned from such an area, who develops an acute 
neurological illness should be screened for ZIKV 
infection. Other cocirculating arboviruses should also 
be considered, such as chikungunya and dengue virus, 
which have been linked to neurological complica-
tions.6 17
Guillain-Barré syndrome
Since the start of the global ZIKV epidemic, 23 coun-
tries have reported an increased incidence in GBS in 
parallel with the rising incidence of ZIKV infection. 
An association between GBS and ZIKV was first estab-
lished in a case–control study in French Polynesia and 
many case reports and series have since substantially 
linked ZIKV and GBS.2 10 18 Although there is no 
proven causality, the most likely explanation is that 
ZIKV infection can trigger GBS. ZIKV is not being 
currently actively being transmitted in Europe, but 
neurologists may well be confronted with GBS cases 
following patient travel to areas with ongoing ZIKV 
transmission (box 3).
GBS is an acute polyradiculoneuropathy and its 
classic form is characterised by a rapidly progres-
sive symmetrical weakness of muscles in legs and 
arms with sensory symptoms and reduced tendon 
reflexes.19 However, the clinical presentation, 
disease progression and outcome may vary exten-
sively between patients, complicating the diagnosis 
and treatment. Several variants of GBS have been 
identified, including the pure motor and parapa-
retic variants and the Miller Fisher syndrome, char-
acterised by ophthalmoplegia, ataxia and areflexia. 
Two-thirds of GBS cases report symptoms of an 
infective disease in the month before disease onset, 
and several pathogens have been associated with 
GBS, including Campylobacter jejuni, cytomega-
lovirus, hepatitis E virus, Mycoplasma pneumoniae 
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Figure 3 MR scan of brain fluid-attenuated inversion recovery (FLAIR) (A) and short tau inversion recovery (STIR) (B, C) 
showing asymmetrical hyperintensities affecting the left nucleocapsular region, thalamus and insula (A), and hyperintense 
longitudinally extensive lesions in the spinal cord. (Copyright © S Karger AG, Basel; Niemeyer et al36).
and Epstein-Barr virus. ZIKV is the latest pathogen 
to be added to this list. The current paradigm is that 
in GBS the preceding infection triggers an immune 
response that causes nerve injury. This has been best 
described in cases with preceding C. jejuni infection 
in which there is carbohydrate mimicry between 
lipo-oligosaccharides on C. jejuni and gangliosides 
on human peripheral nerves and cross-reactive anti-
bodies to these structures.20 Some antibodies are asso-
ciated with clinical variants or electrophysiological 
subtypes of GBS, reflecting in part the distribution of 
gangliosides in peripheral nerves. For instance, the 
ganglioside GM1 is predominantly present on axons 
and the presence of antibodies to GM1 is associated 
with the pure motor and axonal forms of GBS.21 It 
is not yet clear how ZIKV (and viral infections in 
general) can lead to GBS and no particular autoan-
tibody biomarkers that aid in diagnosis have been 
identified. ZIKV might cause nerve damage by direct 
infection, as some patients have reported onset of 
GBS shortly after or even concurrent with infective 
symptoms, and many patients with GBS have ZIKV 
RNA in cerebrospinal fluid (CSF) or serum, indi-
cating ongoing infection.22 However, many other 
reported cases have not had these features, and a 
recent mouse model study showed resistance of the 
peripheral nervous system to infection by ZIKV, indi-
cating that an immune-mediated disease mechanism 
is more likely.23
ZIKV does not seem to be associated with a specific 
GBS phenotype, although most cases have a senso-
rimotor variant with facial nerve palsy, ventilatory 
insufficiency and a demyelinating pattern on clinical 
neurophysiology. There have also been more reported 
cases with paraparesis and intact reflexes than expected 
based on previous studies.10 18 It is not yet clear how 
to interpret these data. They could be a first indica-
tion of a specific clinical phenotype of GBS, but could 
also reflect the cases being labelled as GBS when in 
fact they result from CNS pathology. At present, there 
are no indications that clinicians should deviate from 
standard diagnostic criteria for GBS in a suspected 
ZIKV-related GBS case.
other peripheral nervous system manifestations
There have been sporadic case reports linking other 
peripheral nerve and neuromuscular diseases to 
ZIKV infection, including two cases with acute onset 
of chronic inflammatory demyelinating polyneurop-
athy (CIDP), three cases of transient polyneuritis 
and two cases of myasthenia gravis.24–26 The patients 
with transient polyneuritis had mild distal sensory 
and motor symptoms that resolved within 10 days 
and a positive PCR test for ZIKV in serum and CSF, 
suggesting a self-limiting direct peripheral nerve 
infection by ZIKV.
It is not yet clear if these reported cases are mere 
coincidence or if ZIKV is indeed a causal factor but, in 
patients with flaccid paralysis following ZIKV infec-
tion, clinicians should consider these differential diag-
noses. Furthermore, patients diagnosed with GBS after 
ZIKV need careful follow-up as it may transpire that 
they have acute-onset CIDP.26
meningitis and encephalitis
Inflammation of the meninges (meningitis) or brain 
parenchyma (encephalitis) may result from viral infec-
tion of the brain. There has been no robust study 
associating ZIKV with CNS disease. However, menin-
goencephalitis in the context of recent ZIKV infection 
following foreign travel was first reported in early 
2016 when, 10 days after returning from a cruise 
around New Caledonia, a patient who developed focal 
neurological symptoms and a concurrent rash was 
found to have ZIKV reverse transcription (RT)-PCR 
positive CSF.27
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Figure 4 Algorithm for laboratory investigation of suspected Zika virus infection. CHIKV, chikungunya virus; CSF, cerebrospinal 
fluid; DENV, dengue virus. 
ZIKV-associated encephalitis is associated with 
a range of clinical outcomes, from full recovery 
to death.28 29 It is not yet known whether age or a 
compromised immune system predispose individ-
uals to neurological complications of ZIKV infec-
tion. There may be arboviral systemic symptoms at 
the time of onset of neurological symptoms, encom-
passing confusion; impairment of memory, atten-
tion and processing speed; seizures; and focal motor 
deficits. Pathological changes on electroencephalog-
raphy and MRI may be either diffuse or more focal. 
Currently there are limited data, but by analogy with 
other flaviviruses, ZIKV might be expected to cause 
high signal intensities in the thalamus and other 
basal ganglia.30
myelitis
Myelitis is a spinal cord inflammation that often 
occurs following infection and may appear in isola-
tion, as part of a spectrum of inflammatory nervous 
system pathology or in multisystem disease. Patients 
typically present with rapid-onset motor and sensory 
changes that are usually bilateral and associated with 
a defined sensory level, as with transverse lesions. 
Autonomic dysfunction is common and CSF or MRI 
may give evidence of an inflammatory myelopathy.31
In contrast, some neurotropic viruses, particularly 
enteroviruses such as polio and flaviviruses such as 
Japanese encephalitis virus, directly attack the anterior 
horn cells of the spinal cord. This causes a longitudinal 
anterior myelitis on imaging, and a poliomyelitis-like 
flaccid paralysis clinically.31 32
ZIKV-associated cases of myelitis appear to have 
elements of both transverse and anterior patterns, 
including evidence of motor, sensory and autonomic 
signs, 1–2 weeks after systemic symptom onset. Spinal 
cord lesions on MRI may be anterior and longitudinally 
extensive. Clinical improvement may follow standard 
treatment with corticosteroids or plasma exchange.17 33 34
Acute disseminated encephalomyelitis
Acute disseminated encephalomyelitis (ADEM) is a 
parainfective or postinfective immunological disease 
associated with multifocal neurological symptoms and 
encephalopathy, often occurring in young adults and 
children as is seemingly the case with ZIKV-associated 
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Key points
 ► We advise testing for Zika virus in patients with 
suspected inflammatory neuropathy, unexplained 
myelitis or meningoencephalitis who have been in an 
area with local transmission or who have had sexual 
contact with a confirmed Zika virus case, with or 
without preceding viral symptoms.
 ► The recommended treatment in Zika virus-associated 
neurological disease does not differ from standard 
practice and there are currently no effective antiviral 
drugs.
 ► There are several vaccine candidates against Zika virus 
in development.
ADEM. The relationship between viral infection and 
disease onset is heterogeneous among reported cases 
and there are no known ZIKV-specific clinical or 
MRI features (figure 3).35 36
ZIKV diagnosis in neurological disease
Figure 4 gives an algorithm for laboratory investiga-
tion of suspected ZIKV infection. Recent ZIKV infec-
tion is confirmed through RT-PCR of serum, urine 
and CSF specimens and ZIKV IgM antibody-capture 
ELISA (MAC ELISA) of serum and CSF.37
Reliable detection of viral RNA is possible for around 
14 days in serum and urine. However, as there is a 
variable window of time between viral infection and 
neurological symptoms, PCR may well be performed 
when viral RNA is no longer identifiable.9
ZIKV-specific IgM antibody of serum or CSF can be 
detected from around 4 days to at least 12 weeks after 
exposure, although tests have poor specificity due 
to cross-reactivity with antibodies to other structur-
ally similar viruses such as dengue virus.37 More reliable 
testing for the presence of antibodies that neutralise 
the virus is possible with plaque reduction neutralisa-
tion testing but this goes beyond the capability of most 
hospital laboratories. Detection of virus or antibody 
in the CSF is more specific for CNS disease caused by 
ZIKV, than detection in serum, urine or semen only.
drugs and vaccines against ZIKV
There is no specific antiviral treatment available for 
ZIKV infection. Management of systemic symptoms 
should be supportive and standard practice should 
be followed for cases of ZIKV-related neurological 
disease.
There are several vaccines in development and two 
have entered phase 1 clinical trials, although their 
progress is complicated by multiple factors.38 Most 
importantly, vaccine safety must be guaranteed in 
pregnant women as they are the main population of 
interest, and the possibility of vaccine-induced GBS 
should be considered and prevented. It will likely take 
years before these vaccines are on the market.
ConCluSIon
The rapid emergence of ZIKV as a potential cause of 
severe neurological disease has significant implications 
in endemic areas and beyond. Unsuspecting travellers 
and an abundance of potential vectors have facilitated 
its prolific spread, as illustrated by the number of 
imported cases to date and the extent of at-risk areas 
for future outbreaks. We advise neurologists working 
in areas without current active transmission of the virus 
to consider a preceding ZIKV infection in patients 
with acute inflammation of the central or peripheral 
nervous system returning from areas with ongoing 
active viral transmission, or with sexual partners who 
have returned from such areas. There are currently no 
antiviral drugs available for ZIKV and recommended 
treatment does not differ from standard practice.
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